公开(公告)号：US20250057952A1

公开(公告)日：2025-02-20

申请号：US18562603

申请日：2022-05-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C12N15/90

Abstract: The invention relates to methods of treatment of a solid tumor in a patient in need thereof, comprising administering to the patient: (i) an effective amount of engineered immune cells originating from a donor expressing at their cell surface a Chimeric Antigen Receptor (CAR) directed against Fibroblast Activation Protein (FAP), and (ii) an effective amount of an immunotherapy treatment that elicits an immune response in the patient.

公开(公告)号：US20230228739A1

公开(公告)日：2023-07-20

申请号：US18002229

申请日：2021-07-02

Applicant: CELLECTIS S.A.

Inventor： Xenia NAJ ,  Anne-Sophie Petit ,  Roman Galetto ,  Jean-Pierre Cabaniols

IPC: G01N33/50 ,  G01N33/574 ,  G01N33/566

CPC classification number: G01N33/505 ,  G01N33/574 ,  G01N33/566 ,  G01N2800/7028

Abstract: The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.

公开(公告)号：US10508289B2

公开(公告)日：2019-12-17

申请号：US15031996

申请日：2014-10-24

Applicant: CELLECTIS, S.A.

Inventor： Philippe Duchateau ,  Alexandre Juillerat

IPC: C12N15/90 ,  C12N9/22 ,  A61K48/00 ,  C07K14/195 ,  A61K38/00

Abstract: The present invention is in the field of genetic editing tools and methods of genetic engineering. It relates to the engineering of rare-cutting endonucleases designed to contract highly repetitive motives in chromosomes, which are at the origin of certain genetic diseases, in particular the so-called “triplet repeat diseases”, such as the Huntington disease. The invention encompasses the method for contracting the repetitive motives, the rare-cutting endonucleases for use to contract repetitive motives in a gene subjected to repeat disorder, the polynucleotides and vectors encoding thereof as well as the resulting pharmaceutical compositions.

公开(公告)号：US10378007B2

公开(公告)日：2019-08-13

申请号：US14424757

申请日：2013-08-30

Applicant: CELLECTIS, S.A.

Inventor： Alexandre Juillerat ,  Philippe Duchateau

IPC: C12N15/10 ,  C07K14/195 ,  C07H21/00 ,  C12N15/82 ,  C12N15/63

Abstract: Methods for improving or modulating targeting specificity of TALE proteins by introducing alternative RVDs into their modular nucleic acid binding domains. Polynucleotides encoding TALE proteins having alternative targeting specificity towards a nucleic acid target sequence. TALE proteins having alternative targeting specificity towards a nucleic acid target sequence and methods of making and using them.

公开(公告)号：US20180237765A1

公开(公告)日：2018-08-23

申请号：US15956103

申请日：2018-04-18

Applicant: Cellectis S.A.

Inventor： Richard E Walters ,  Alan D King

IPC: C12N13/00

CPC classification number: C12N13/00 ,  A61K9/0009 ,  C12M1/42 ,  C12M3/00 ,  C12M3/006 ,  C12M3/02 ,  C12M35/02 ,  C12M45/07 ,  C12N15/87 ,  H02K1/146 ,  H02K1/246 ,  H02K19/103

Abstract: An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm−1 ) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the vesicles in the chamber is substantially uniform.

公开(公告)号：US20160273003A1

公开(公告)日：2016-09-22

申请号：US15080232

申请日：2016-03-24

Applicant: Cellectis S.A.

Inventor： Philippe DUCHATEAU ,  Christophe PEREZ ,  Sylvia BRUNEAU ,  Jean-Pierre CABANIOLS ,  Julianne SMITH ,  Agnes GOUBLE

IPC: C12N15/90 ,  C07K14/435 ,  C12N15/86 ,  C12N9/22 ,  A61K38/46 ,  C12N7/00

CPC classification number: C12N15/907 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0337 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/465 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/435 ,  C07K2319/81 ,  C12N7/00 ,  C12N9/22 ,  C12N15/1058 ,  C12N15/8509 ,  C12N15/86 ,  C12N15/90 ,  C12N2730/10143 ,  C12N2799/022 ,  C12N2800/80 ,  C12N2830/002 ,  C12N2830/55 ,  C12N2840/20 ,  C12N2840/44 ,  C12Y301/00 ,  C12Y301/21004

Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.

Abstract translation: 单链归巢内切核酸酶，其包含具有登录号pdb 1g9y的氨基酸序列的I-CreI的第一变体和在单个多肽中具有登录号pdb 1g9y的氨基酸序列的I-CreI变体的第二变体。

公开(公告)号：US11778993B2

公开(公告)日：2023-10-10

申请号：US14384957

申请日：2013-03-15

Applicant: CELLECTIS, S.A.

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Claudia Bertonati

IPC: A01K67/027 ,  C12N15/63 ,  C12N5/10 ,  C07K5/06 ,  C07K14/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/82

CPC classification number: A01K67/0275 ,  C07K5/06 ,  C07K14/00 ,  C12N5/10 ,  C12N9/22 ,  C12N15/63 ,  C12N15/10 ,  C12N15/82

Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. The present invention also concerns methods to use these proteins. The present invention also relates to vectors, compositions and kits in which RVD domains and Transcription Activator-Like Effector (TALE) proteins of the present invention are used.

公开(公告)号：US20230212613A1

公开(公告)日：2023-07-06

申请号：US17996733

申请日：2021-05-06

Applicant: CELLECTIS S.A.

Inventor： Ming YANG ,  Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Patrick HONG

IPC: C12N15/90 ,  C07K14/725 ,  C12N9/22 ,  C12N5/0783

CPC classification number: C12N15/907 ,  C07K14/7051 ,  C12N9/22 ,  C12N5/0636 ,  C12N2310/20

Abstract: The present disclosure provides methods for targeted insertion of an exogenous sequence at a genomic locus in a cell, wherein said insertion is induced by a sequence-specific endonuclease that has cleavage activity at said locus, at least 5 hours before the introduction into said cell of a DNA template comprising said exogenous sequence.

公开(公告)号：US11578318B2

公开(公告)日：2023-02-14

申请号：US15956103

申请日：2018-04-18

Applicant: Cellectis S.A.

Inventor： Richard E Walters ,  Alan D King

IPC: C12N13/00 ,  C12M1/00 ,  C12N15/87 ,  C12M1/42 ,  C12M3/00 ,  C12M3/02 ,  H02K1/24 ,  H02K1/14 ,  H02K19/10 ,  A61K9/00

Abstract: An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm−1) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the vesicles in the chamber is substantially uniform.

公开(公告)号：US20150218230A1

公开(公告)日：2015-08-06

申请号：US14424757

申请日：2013-08-30

Applicant: CELLECTIS, S.A.

Inventor： Alexandre Juillerat ,  Philippe Duchateau

IPC: C07K14/195 ,  C07H21/00

CPC classification number: C07K14/195 ,  C07H21/00 ,  C07K2319/80 ,  C12N15/10 ,  C12N15/102 ,  C12N15/63 ,  C12N15/8216 ,  C12N2501/60

Abstract: Methods for improving or modulating targeting specificity of TALE proteins by introducing alternative RVDs into their modular nucleic acid binding domains. Polynucleotides encoding TALE proteins having alternative targeting specificity towards a nucleic acid target sequence. TALE proteins having alternative targeting specificity towards a nucleic acid target sequence and methods of making and using them.

Abstract translation: 通过将替代RVD引入其模块化核酸结合结构域来改善或调节TALE蛋白的靶向特异性的方法。 编码具有针对核酸靶序列的替代靶向特异性的TALE蛋白的多核苷酸。 具有针对核酸靶序列的替代靶向特异性的TALE蛋白质及其制备和使用它们的方法。